Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Carl Wonders Clear advanced filters

    • Marco Bassetto
    • Thomas Reichl
    • Henrik Mouritsen
    ResearchOpen Access
    Nature
    Volume: 629, P: E6-E7

  • Large-vessel vasculitis is the most common primary vasculitis in adults, manifesting as inflammation of the aorta and its major branches. This Primer reviews the epidemiology, pathophysiology, diagnosis and management of this disease, highlights its effects on patient quality of life, and discusses future research questions.

    • Dan Pugh
    • Maira Karabayas
    • Neeraj Dhaun
    Reviews
    Nature Reviews Disease Primers
    Volume: 7, P: 1-23

  • A new paper shows that the transcription factor Dlx1, known to be involved in neuronal migration, is also necessary for interneuron survival. Mice lacking Dlx1 show subtype-specific loss of interneurons, a reduction in inhibitory currents and generalized seizures.

    • Carl Wonders
    • Stewart Anderson
    News & Views
    Nature Neuroscience
    Volume: 8, P: 979-981

  • Interneurons are a diverse set of neurons that comprise various morphological, physiological and chemical characteristics. Recent work has shed light on the origins and specification of distinct subtypes of cortical interneurons, which could drive new discoveries on cortical function.

    • Carl P. Wonders
    • Stewart A. Anderson
    Reviews
    Nature Reviews Neuroscience
    Volume: 7, P: 687-696

  • The National Institute of Neurological Disorders and Stroke (NINDS) held an open workshop on April 23 and 24, 2024 to evaluate the gap between the current understanding of Parkinson’s disease (PD) and the development of therapeutics for treating PD. Representatives from key stakeholder groups discussed strategies for leveraging research to bridge this gap. Sessions focused on PD heterogeneity, target validation, development of tools and resources to facilitate therapeutics development, biomarker discovery and use, similarities and differences with PD-adjacent neurodegenerative diseases, and best practices for accelerating the therapeutics development process. Here are some of the main takeaways from the workshop.

    • Neel T. Dhruv
    • Sarah Robinson Schwartz
    • Amir P. Tamiz
    News & ViewsOpen Access
    npj Parkinson's Disease
    Volume: 11, P: 1-6